(This "Intro Box" is NOT maintained by Amarantus BioScience, Inc. and is intended solely as a quick information source on ihub. For more detailed, up-to-date information on Amarantus BioScience, Inc., please go the company website.)
Amarantus BioScience, Inc. ("Amarantus") is a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis (programmed cell death).
The Company's lead therapeutic program Mesencephalic-Astrocyte-derived Neurotrophic Factor, or MANF is a targeted therapeutic to address the underlying Programmed Cell Death (Apoptosis) associated with a wide range of devastating human disorders. The Company's lead diagnostic program, NuroPro®, is aimed at developing diagnostic blood tests that are capable of early identification of apoptosis-related medical conditions while tracking their progression over time. Both programs will initially target Parkinson's disease.
Neurodegenerative diseases such as Parkinson's, ALS and Alzheimer's as well as Cardiovascular Disease such as Myocardial Infarction, Angina, Coronary Artery Disease and Heart Failure are in need of treatments that address the region specific apoptosis associated with each disorder. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's Disease and other human diseases.
Amarantus owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and TBI. The Company also has a diagnostic program led by NuroPro® which is aimed at developing diagnostic blood tests that are capable of early identification of apoptosis-related medical conditions while tracking their progression over time.
Amarantus' Management Team and Board of Advisors have designed a business strategy to formulate and advance pre-clinical and clinical programs for the Company's product candidates through successive de-risking milestones in order to maximize their commercial potential. The Company is also focused on making the assets attractive partnering targets for product development focused biotechnology, pharmaceutical, medical device and diagnostic companies.
Amarantus BioScience at Biotech Showcase 2013
Jan 8, 2013
AMBS DD : http://investorshub.advfn.com/boards/read_msg.aspx?message_id=82688006
Medical Dictionary (some often-used terms in AMBS PRs)
The substania nigra is an area of pigmented cells in the midbrain which is responsible for producing the neurotransmitter dopamine. This section of the brain plays an important role in the control of movement, and it also appears to interact in the process of addiction, as well. If you view a brain in cross-section, the substantia nigra is located in the midbrain, right at the tip of the brainstem.
The striatum is also called the striate body. It includes the caudate nucleus and the lentiform nucleus. The term striatum (striate) refers to the layered appearance of bands of gray matter that course from one of these nuclei to the other and represent the connections between them.
In living tissues, reinnervation describes the process by which post-synaptic neurons form new synapses or increase existing synaptic efficacy in order to compensate for a lack of pre-synaptic input from dead or otherwise dysfunctional pre-synaptic neurons.
Glial cell-derived neurotrophic factor, also known as GDNF is a protein that, in humans, is encoded by the GDNF gene. GDNF is a small protein that potently promotes the survival of many types of neurons.[2
Myocardial infarction (MI) or acute myocardial infarction (AMI), commonly known as a heart attack